DJIA 16,887.54 -73.03 -0.43%
NASDAQ 4,413.99 -35.57 -0.80%
S&P 500 1,969.37 -8.97 -0.45%
market minute promo

Vertex Pharmaceuticals (NASDAQ: VRTX)

95.56 -0.19 (-0.20%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

VRTX $95.56 -0.20%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $95.48
Previous Close $95.75
Daily Range $95.30 - $96.29
52-Week Range $58.06 - $99.74
Market Cap $22.6B
P/E Ratio -61.77
Dividend (Yield) $0.00 (0.0%)
Volume 283,543
Average Daily Volume 2,978,897
Current FY EPS -$2.74

Sector

Healthcare

Industry

Drugs

Vertex Pharmaceuticals (VRTX) Description

The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. Website: http://www.vrtx.com/

News & Commentary Rss Feed

3 Things to Watch at Gilead

Hepatitis C is important, but only for two of the thee points.

Should You Buy Vertex Pharmaceuticals (VRTX) Ahead of Earnings? - Tale of the Tape

5 Huge Biotech Catalysts Right Around the Corner for Top Stocks

Stock Market News for July 24, 2014 - Market News

Vertex Is Poised For An Earnings Breakout

Biotech Stock Roundup: AbbVie Woos Shire with Revised Offer, Sarepta Slips on Eteplirsen Data - Anal

Biotech Stock Roundup: AbbVie Woos Shire with Revised Offer, Sarepta Slips on Eteplirsen Data - Analyst Blog

Fed: Beware of social media, biotech stocks

Nasdaq 100 Movers: VRTX, MYL

Vertex Pharmaceuticals Inc Stock Upgraded (VRTX)

Vertex Pharmaceuticals Inc. (VRTX): New Analyst Report from Zacks Equity Research - Zacks Equity Res

Vertex Pharmaceuticals Inc. (VRTX): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

Merck, Gilead Lead Race To Eradicate Hepatitis C

See More VRTX News...

VRTX's Top Competitors

VRTX $95.56 (-0.20%)
Current stock: VRTX
AMGN $121.96 (-0.72%)
Current stock: AMGN
GILD $90.77 (1.04%)
Current stock: GILD
BIIB $333.00 (-0.73%)
Current stock: BIIB